Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARL | Q9H300 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 6/20 | 0.36 |
| ▸ | CA1 | P00915 | 5/20 | 0.36 |
| ▸ | CA9 | Q16790 | 3/20 | 0.36 |
| ▸ | CA5A | P35218 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA7 | P43166 | 2/20 | 0.36 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4138404 | 0.86 | PARL (0.41) | PARLCA2CA1CA9CA5A | |
| SCHEMBL22265082 | 0.84 | PARL (0.40) | PARLCA2CA1CA9CA5A | |
| SCHEMBL22265083 | 0.83 | PARL (0.39) | PARLTDP1PTGS2HTR6PSIP1 | |
| SCHEMBL22265193 | 0.83 | TDP1 (0.39) | PARLTDP1PTGS2HTR6PSIP1 | |
| SCHEMBL2270234 | 0.82 | CA1 (0.43) | PARLCA2CA1CA9CA5A | |
| SCHEMBL22265195 | 0.78 | PARL (0.35) | PARLCA2TDP1PTGS2ALDH1A1 | |
| SCHEMBL2058282 | 0.77 | PARL (0.46) | PARLCA2CA1CA9CA5A | |
| SCHEMBL16863993 | 0.76 | TSHR (0.41) | PARLTDP1PTGS2HTR6PSIP1 | |
| SCHEMBL3447252 | 0.76 | PSIP1 (0.45) | PARLCA2CA1CA9CA5A | |
| SCHEMBL11049643 | 0.76 | PARL (0.44) | PARLCA2CA1CA9CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760737-B2 | Process for manufacturing 4-(2,2,3,3-tetrafluoropropyl)morpholine | ADVERIO PHARM GmbH (DE) | 2023-09-19 | — | — | US | disclosed |
| EP-3914588-A1 | PROCESS FOR MANUFACTURING 4-(2,2,3,3-TETRAFLUOROPROPYL)MORPHOLINE | Adverio Pharma GmbH (DE) | 2021-12-01 | — | — | EP | disclosed |
| WO-2020152010-A1 | PROCESS FOR MANUFACTURING 4-(2,2,3,3-TETRAFLUOROPROPYL)MORPHOLINE | ADVERIO PHARMA GMBH (DE) | 2020-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760737-B2 | Process for manufacturing 4-(2,2,3,3-tetrafluoropropyl)morpholine | CYP4F3, CYP4F2, TNNT2 | PARL 1536/4885CA2 2118/4885CA1 4706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.